Login to Your Account

Analyst: Avastin Data Could be 'Wild Card'

Roche Goes Hostile, Takes Lower Offer to Genentech Shareholders

By Jennifer Boggs

Monday, February 2, 2009
With negotiations seemingly at a stand-still six months after Genentech Inc. rejected as too low a $44 billion buyout offer from majority holder Roche Holdings AG, the Swiss drugmaker clearly hopes to set the deal back in motion, but analysts say it's doubtful the biotech's minority shareholders will be amenable to a reduced bid. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription